NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
45963-0640-57 | 45963-0640 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Jan. 4, 2018 | No Longer Used | |
45963-0640-77 | 45963-0640 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Jan. 4, 2018 | Jan. 31, 2021 | No Longer Used |
70860-0216-10 | 70860-0216 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 10, 2019 | July 31, 2021 | No Longer Used |
00517-0920-08 | 00517-0920 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | April 1, 2017 | In Use | |
65219-0160-10 | 65219-0160 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Nov. 11, 2019 | In Use | |
60505-6177-08 | 60505-6177 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Aug. 19, 2019 | Jan. 31, 2023 | No Longer Used |
14789-0013-10 | 14789-0013 | Busulfan | Busulfan | 60.0 mg/10mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Sept. 15, 2023 | In Use | |
00574-0106-01 | 00574-0106 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 1, 2014 | In Use | |
00574-0106-03 | 00574-0106 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 1, 2014 | In Use | |
00781-2119-01 | 00781-2119 | Bromocriptine Mesylate | Bromocriptine Mesylate | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | June 28, 1978 | Nov. 30, 2013 | No Longer Used | |
00781-2119-31 | 00781-2119 | Bromocriptine Mesylate | Bromocriptine Mesylate | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | June 28, 1978 | Nov. 30, 2013 | No Longer Used | |
00781-5325-01 | 00781-5325 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 13, 1998 | In Use | |
00781-5325-31 | 00781-5325 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 13, 1998 | In Use | |
65841-0654-01 | 65841-0654 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 23, 2009 | In Use | |
65841-0654-06 | 65841-0654 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 23, 2009 | In Use | |
68084-0375-11 | 68084-0375 | Bromocriptine Mesylate | Bromocriptine Mesylate | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | March 1, 2009 | Sept. 30, 2009 | No Longer Used | |
68084-0375-21 | 68084-0375 | Bromocriptine Mesylate | Bromocriptine Mesylate | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | March 1, 2009 | Sept. 30, 2009 | No Longer Used | |
68382-0110-01 | 68382-0110 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 23, 2009 | In Use | |
68382-0110-06 | 68382-0110 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 23, 2009 | In Use | |
00378-7096-01 | 00378-7096 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 1, 2013 | In Use | |
00378-7096-93 | 00378-7096 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | June 17, 2013 | In Use | |
00179-0165-70 | 00179-0165 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Oct. 10, 2014 | June 30, 2017 | In Use |
00179-0225-70 | 00179-0225 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Feb. 14, 2017 | Jan. 31, 2018 | In Use |
00378-2042-01 | 00378-2042 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | June 5, 2013 | July 31, 2020 | No Longer Used |
00378-2042-93 | 00378-2042 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | June 5, 2013 | July 31, 2020 | No Longer Used |
54868-5667-00 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-01 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-02 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-03 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
63304-0158-01 | 63304-0158 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0158-30 | 63304-0158 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0962-01 | 63304-0962 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0962-30 | 63304-0962 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
68151-1305-00 | 68151-1305 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 1, 2014 | No Longer Used | |
69189-7096-01 | 69189-7096 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | March 8, 2016 | May 24, 2017 | No Longer Used |
60687-0286-11 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 7, 2017 | In Use | |
60687-0286-21 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 27, 2017 | Sept. 30, 2024 | In Use |
00069-0135-01 | 00069-0135 | Bosutinib monohydrate | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 4, 2012 | In Use | |
00069-0136-01 | 00069-0136 | Bosutinib monohydrate | Bosulif | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 4, 2012 | In Use | |
63539-0117-01 | 63539-0117 | Bosutinib monohydrate, Bosutinib | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 4, 2012 | In Use | |
43598-0865-60 | 43598-0865 | Bortexomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Nov. 1, 2019 | In Use | |
50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
51817-0586-01 | 51817-0586 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
63323-0821-10 | 63323-0821 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
68001-0540-36 | 68001-0540 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
70860-0225-10 | 70860-0225 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 6, 2022 | In Use | |
00143-9098-01 | 00143-9098 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 27, 2022 | In Use | |
00409-1700-01 | 00409-1700 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 27, 2022 | In Use | |
00781-3258-70 | 00781-3258 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | May 31, 2022 | In Use | |
68001-0541-36 | 68001-0541 | Bortezomib | Bortezomib | 3.5 mg/3.5mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 31, 2022 | In Use |
Found 10,000 results in 15 milliseconds — Export these results